Minirin Melt (Desmopressin)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that increases cyclic AMP, causing aquaporin‑2 water channels to move to the cell surface, which enhances water reabsorption and concentrates urine. In hemophilia A, the same receptor activation promotes release of clotting factors from endothelial stores.

The exact dose of Minirin Melt is individualized by the prescribing clinician based on the patient’s age, weight, severity of the condition, renal function, and response to therapy. Dosing adjustments may be required for elderly patients, those with impaired kidney function, or when concomitant medications affect water balance.

Safety data for desmopressin in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when possible. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To request Minirin Melt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Minirin Melt offers a sublingual melt formulation that provides rapid absorption and convenient administration without the need for injections or nasal sprays. Compared with traditional oral tablets, the melt may have a quicker onset, while still delivering the same selective V2‑receptor activity as other desmopressin products. Choice of formulation depends on patient preference, adherence considerations, and specific clinical scenarios.

Minirin Melt should be stored at ambient temperature, below 25 °C, in its original blister pack or container. Protect the tablets from moisture and direct sunlight to maintain potency and prevent degradation.

The tablet is placed under the tongue and allowed to melt completely without chewing or swallowing whole. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal absorption through the sublingual mucosa.

The most critical safety concerns are severe hyponatremia and water intoxication, which can lead to seizures, confusion, cerebral edema, or even coma. Patients should be monitored for sudden changes in mental status, excessive weight gain, or persistent headache, and fluid intake should be managed according to medical guidance.

Minirin Melt is contraindicated in individuals with known hypersensitivity to desmopressin or any excipients, in patients with uncontrolled hypertension, and in those with severe renal impairment where water clearance is markedly reduced. Caution is also advised for patients with a history of hyponatremia or chronic fluid overload.